| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 3086 | 2019 |
| Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open … T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ... The Lancet Oncology 21 (12), 1563-1573, 2020 | 672 | 2020 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 514 | 2021 |
| Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ... The Lancet 398 (10295), 131-142, 2021 | 250 | 2021 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 214 | 2022 |
| Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non–clear cell renal cell carcinoma DF McDermott, JL Lee, M Ziobro, C Suarez, P Langiewicz, VB Matveev, ... Journal of Clinical Oncology 39 (9), 1029-1039, 2021 | 195 | 2021 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 145 | 2022 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of … BI Rini, ER Plimack, V Stus, T Waddell, R Gafanov, F Pouliot, D Nosov, ... Journal of Clinical Oncology 39 (15_suppl), 4500-4500, 2021 | 133 | 2021 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor … BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... Journal of Clinical Oncology 37 (15_suppl), 4500-4500, 2019 | 132 | 2019 |
| Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma: results from cohort A of KEYNOTE-427 DF McDermott, JL Lee, C Szczylik, F Donskov, J Malik, B Alekseev J Clin Oncol 36 (Suppl. 15_suppl), 4500, 2018 | 122 | 2018 |
| Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma DF McDermott, JL Lee, GA Bjarnason, JMG Larkin, RA Gafanov, ... Journal of Clinical Oncology 39 (9), 1020-1028, 2021 | 117 | 2021 |
| Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. ER Plimack, BI Rini, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ... Journal of Clinical Oncology 38 (15_suppl), 5001-5001, 2020 | 77 | 2020 |
| Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ... Journal of Clinical Oncology 41 (17_suppl), LBA4501-LBA4501, 2023 | 60 | 2023 |
| First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B. DF McDermott, JL Lee, M Ziobro, RA Gafanov, VB Matveev, C Suárez, ... Journal of Clinical Oncology 37 (7_suppl), 546-546, 2019 | 60 | 2019 |
| Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III … ES Antonarakis, SH Park, JC Goh, SJ Shin, JL Lee, N Mehra, ... Journal of Clinical Oncology 41 (22), 3839-3850, 2023 | 56 | 2023 |
| Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. T Powles, JE Gschwend, Y Loriot, J Bellmunt, L Geczi, C Vulsteke, ... Journal of Clinical Oncology 35 (15_suppl), TPS4590-TPS4590, 2017 | 52 | 2017 |
| Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma J Bedke, BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, ... European Urology 82 (4), 427-439, 2022 | 46 | 2022 |
| KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer DP Petrylak, R Ratta, R Gafanov, G Facchini, JM Piulats, G Kramer, ... Future Oncology 17 (25), 3291-3299, 2021 | 46 | 2021 |
| Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study ER Plimack, T Powles, V Stus, R Gafanov, D Nosov, T Waddell, ... European Urology 84 (5), 449-454, 2023 | 44 | 2023 |
| IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) JS de Bono, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ... Annals of Oncology 31, S1153-S1154, 2020 | 42 | 2020 |
Frederic PouliotCHU de QuébecE-mail confirmado em crchudequebec.ulaval.ca
